论文部分内容阅读
目的探讨新辅助化疗对局部晚期非小细胞肺癌生存率的影响。方法可切除的局部晚期非小细胞肺癌119例;分两组:新辅助化疗+手术组(A组)59例,直接手术组(B组)60例。对两组患者的临床资料进行统计学分析。结果 A组的总有效率为54.23%(32/59),病期下调率20.33%(12/59);手术切除率和完全性切除率分别为91.5%和81.4%,高于对照组为81.7%和68.3%。两组患者术后1、3、5年生存率分别为79.66%、50.88%、21.43%和71.19%、35.09%、14.29%,两者比较差异有统计学意义(P<0.05);术后平均生存时间分别为32.909月和28.046月,差异有统计学意义(P<0.05),而术后并发症发生率两组比较差异无统计学意义(P>0.05)。结论新辅助化疗可显著提高局部晚期非小细胞肺癌的手术切除率,延长生存期,较直接手术组有优势,且未增加术后并发症,是安全可行的。
Objective To investigate the effect of neoadjuvant chemotherapy on the survival rate of locally advanced non-small cell lung cancer. Methods A total of 119 resectable locally advanced non-small cell lung cancer patients were divided into two groups: 59 cases in neoadjuvant chemotherapy plus surgery group (A group) and 60 cases in direct surgery group (B group). The clinical data of two groups of patients were statistically analyzed. Results The total effective rate was 54.23% (32/59) in group A, and the down-regulation rate was 20.33% (12/59) in group A. Surgical resection rate and complete resection rate were 91.5% and 81.4% respectively, which were higher than 81.7% in control group % And 68.3%. The 1, 3, 5 year survival rates of the two groups were 79.66%, 50.88%, 21.43% and 71.19%, 35.09% and 14.29% respectively, with significant difference between the two groups (P <0.05) The survival time was 32.90 months and 28.46 months, the difference was statistically significant (P <0.05), while the incidence of postoperative complications was no significant difference between the two groups (P> 0.05). Conclusions Neoadjuvant chemotherapy can significantly improve the surgical resection rate and prolong the survival of locally advanced non-small cell lung cancer, which is superior to the direct operation group and does not increase postoperative complications, which is safe and feasible.